Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AdvanZ-4: Immune reconstitution with dolutegravir vs boosted darunavir-based ART in severely immunosuppressed HIV-1 patients
2014-002281-70Phase 4Active
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of abacavir, darunavir and ritonavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoints: Change in CD4+ T cell count at 48 weeks and Change in CD4+ T cell count at 96 weeks. Started Dec 2014; status: active.
02
Drugs
abacavirdarunavirritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2014-002281-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002281-70.